ICI Diagnostics

QF-Pro® can advance your immune checkpoint clinical trials

Click here to try QF-Pro®

PD-1/PD-L1 interaction state predicts patient response and survival in NSCLC

Unlike PD-L1 score, determination of PD-1/PD-L1 interaction state by QF-Pro® predicts patient outcome and treatment response in NSCLC. Those patients with a higher PD-1/PD-L1 interaction experienced increased survival rates due to the correct therapeutic targeting of this checkpoint.

Read more

PD-L1 scores miss 24.5% of patients for 1st line immunotherapy

When all NSCLC patients are analysed by QF-Pro®, it is seen that 24.5% of patients with a low PD-L1 score have high PD-1/PD-L1 interaction. These patients may miss life saving first-line mono-therapies based on the current gold standard biomarker. Conversely, 22.5% of patients with high PD-L1 scores will not respond due to low interaction status.

Read more

QF-Pro® predicts treatment response even in patients with TPS <1%

QF-Pro® was used to assess PD-1/PD-L1 interaction states in all patients with a PD-L1 TPS <1%. Here, those patients with an interaction state above our proposed threshold (2% FRET efficiency) responded significantly better to treatment than those patients with no interaction state.

Read more

Try QF-Pro® today to see how it can advance your clinical trials.

QF-Pro® is a versatile platform which has to potential to revolutionise clinical trials in the field of immune checkpoint inhibitors. Whilst we have exemplified the power of QF-Pro® by assessing PD-1/PD-L1interaction states, QF-Pro® can be used to quantify the interaction state of any immune checkpoint and is already tested in CTLA-4/CD80 and TIGIT/CD155.

Click here to try QF-Pro®

© Copyright HAWK Biosystems . All rights reserved.